Table 1.

Clinical Characteristics

	Whole cohort (n=20)	mPAP <35 (n=11)	mPAP ≥35 (n=9)
Age (years)	86±10	85±10	86±10
Female gender	50	45	56
Body surface area (m2)	1.9±0.3	1.8±0.3	1.9±0.3
Systolic blood pressure (mmHg)†	153±21	145±20	163±17*
Diastolic blood pressure (mmHg)†	72±9	69±7	75±11
Prior myocardial infarction	10	9	11
Coronary artery disease	65	55	78
Hypertension	95	91	100
Atrial arrhythmia	25	9	44
Diabetes mellitus	45	27	67
Obstructive lung disease	35	22	50
NYHA functional class
II	10	18	0
III	65	73	56
IV	25	9	44
Glomerular filtration rate (mL/min/1.73m2)‡	57±22	64±24	50±17
B-type natriuretic peptide (pg/mL)	741±813	454±312	1092±1094
ACE-inhibitors or ARBs	30	27	33
ß-blockers	75	73	78
Calcium channel blockers	15	18	11
Diuretics	80	73	89
Statins	60	73	44
Prior use of a PDE5 inhibitor	10	18	0
Aortic valve area (cm2)	0.7±0.2	0.6±0.2	0.7±0.2
Ejection fraction (EF) (%)	60±14	65±13	53±13
Reduced EF (<50%)	30	18	44
LV mass index (g/m2)	155±22	152±17	160±29
Relative wall thickness	0.6±0.2	0.7±0.2	0.6±0.1
Aortic regurgitation severity
0	30	27	33
1	50	55	44
2	20	18	22
Mitral regurgitation severity
0	15	27	0
1	50	55	44
2	35	18	56

All values are mean ± SD or % unless otherwise specified.

^*p<0.05, comparing those with mPAP <35 vs. mPAP ≥35.

^†Obtained in the holding area outside the cardiac catheterization procedure room (cuff pressure).

^‡Estimated by the Modification of Diet in Renal Disease Study method.

Aortic and mitral regurgitation were graded: 0 (none), 1 (mild), 2 (moderate), 3 (moderately severe), 4 (severe).